Diabetes Drugs Ref

Diabetes Drugs Reference — evidence-based pharmacology reference for diabetes drug classes. Based on NICE NG28 2022, ADA Standards of Care 2024, and SIGN 154. FREE — no purchase needed: — SGLT2 Inhibitors: empagliflozin, dapagliflozin, canagliflozin, ertugliflozin with doses, CV outcomes and renal thresholds FULL ACCESS — £14.99/year unlocks: — GLP-1 Receptor Agonists: semaglutide, liraglutide, dulaglutide, tirzepatide — DPP-4 Inhibitors: sitagliptin, linagliptin, alogliptin, vildagliptin — Metformin: doses, eGFR thresholds, B12 monitoring — Sulfonylureas: gliclazide, glipizide, glibenclamide — Insulin: basal, bolus, premixed, ultra-long analogues — Thiazolidinediones, Meglitinides, Alpha-glucosidase inhibitors — Prescribing Guide: renal dosing table, contraindications, monitoring — HbA1c Targets: individualised targets by patient group — CV Outcomes Trials: EMPA-REG, LEADER, DECLARE, DAPA-HF, REWIND, SURPASS — Hypoglycaemia Management: severity grading, treatment protocol — Sick Day Rules: SADMAN, JBDS inpatient protocol — Special Situations: pregnancy, CKD, elderly, perioperative — References: 25+ tappable citations, NICE, NEJM, Lancet, ADA Subscription renews automatically at £14.99/year unless cancelled at least 24 hours before the end of the current period. Manage in App Store Settings > Subscriptions. For use by qualified healthcare professionals only. Always verify doses against the current BNF and SmPC before prescribing.